BioTelemetry, a Philips company

Webinars

Assessing NASH: Discover the Non-invasive Techniques

In this free webinar, Richard Ehman, MD from the Mayo Clinic and BioTel Research’s Jonathan Riek, PhD, VP, Musculoskeletal and Metabolic Imaging discuss non-invasive ways to assess NASH using imaging, including proton density fat fraction (PDFF), T1 relaxometry, magnetic resonance elastography (MRE), and the latest advances in MRE.

Body Composition in Clinical Trials – From BMI to MRI

In this free webinar, BioTel Research’s Vice President of Musculoskeletal and Metabolic Imaging, Jonathan Riek, PhD, and AMRA’s Chief Scientific Officer & Co-Founder, Olof Dahlqvist Leinhard, PhD, present alternative, noninvasive imaging methods to determine body composition. Watch Webinar

Managing Multi-protocol Programs & Building Efficient Partnerships

Join Svetlana Kolchinsky, Director of Project Operations, as she discusses how to manage multi-protocol programs and build efficiencies while being a good partner. Key topics include next level planning for risk management and project/program oversight, successful project delivery and lessons learned.

Advanced Imaging in Oncology

In this free webinar, industry experts Edward Ashton, PhD and Polina Voloshko, MD will discuss the growing range of imaging modalities and analysis methods that are available for use in your clinical trials during oncology drug development.

Detecting Arrhythmias in Clinical Trials Using ECG Monitoring

Please join us for this free webinar on trends in event and continuous ECG monitoring, and implications for clinical trials of both medical devices and drug therapies. Presented by Polina Voloshko, MD, Chief Medical Officer, BioTel Research. Download Full Slide Presentation 

Imaging for NAFLD/NASH: Current State and Future Trends Webinar

Non-alcoholic fatty liver disease (NAFLD) is the most common diffuse liver disease, with a worldwide prevalence of 20-46 percent. NAFLD can be subdivided into simple steatosis and nonalcoholic steatohepatitis (NASH). Patients with non-alcoholic fatty liver disease (NAFLD) are at risk of steatohepatitis and progressive liver fibrosis culminating in cirrhosis, typically over

Imaging for NAFLD/NASH: Current State and Future Trends Webinar

Non-alcoholic fatty liver disease (NAFLD) is the most common diffuse liver disease, with a worldwide prevalence of 20-46 percent. NAFLD can be subdivided into simple steatosis and nonalcoholic steatohepatitis (NASH). Patients with non-alcoholic fatty liver disease (NAFLD) are at risk of steatohepatitis and progressive liver fibrosis culminating in cirrhosis, typically over a

Learn More

Advanced Imaging in Oncology

In this free webinar, industry experts Edward Ashton, PhD and Polina Voloshko, MD will discuss the growing range of imaging modalities and analysis methods that are available for use in your clinical trials during oncology drug development.

Learn More

Body Composition in Clinical Trials – From BMI to MRI

In this free webinar, BioTel Research’s Vice President of Musculoskeletal and Metabolic Imaging, Jonathan Riek, PhD, and AMRA’s Chief Scientific Officer & Co-Founder, Olof Dahlqvist Leinhard, PhD, present alternative, noninvasive imaging methods to determine body composition. Watch Webinar

Learn More

Assessing NASH: Discover the Non-invasive Techniques

In this free webinar, Richard Ehman, MD from the Mayo Clinic and BioTel Research’s Jonathan Riek, PhD, VP, Musculoskeletal and Metabolic Imaging discuss non-invasive ways to assess NASH using imaging, including proton density fat fraction (PDFF), T1 relaxometry, magnetic resonance elastography (MRE), and the latest advances in MRE.

Learn More